Hemolysis, Icterus, and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis, 1st Edition
This document provides background information on mechanisms of hemolysis, icterus, lipemia/turbidity (HIL) interference; intended usefulness of HIL indices; establishment of HIL alert indices; availability of automated HIL detection systems; and interpretation, strengths, limitations, and verification of HIL indices in the clinical laboratory.
Members: $42.00 → $119.00Nonmembers: $140.00
Chairholder: Merle B. Smith, MBA, MS, MT(ASCP)
Date of Publication: July 13, 2012
ISBN Number: 1-56238-799-5
Order Code PDF: C56AE
Order Code Print: C56A
C56 Additional Details
The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.
This document is no longer being reviewed as part of our consensus process. However, because of its usefulness to a limited segment of the healthcare community, we are continuing to make the document available for its informational content.